CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 53 filers reported holding CYTOSORBENTS CORP in Q3 2023. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,821,112 | -47.2% | 1,502,696 | +0.9% | 0.00% | -40.0% |
| Q2 2023 | $5,344,236 | +2.1% | 1,488,645 | -3.8% | 0.01% | 0.0% |
| Q1 2023 | $5,232,629 | +124.8% | 1,547,923 | +1.2% | 0.01% | +150.0% |
| Q4 2022 | $2,327,445 | +16.2% | 1,529,095 | +3.3% | 0.00% | 0.0% |
| Q3 2022 | $2,003,000 | -31.4% | 1,479,570 | +11.4% | 0.00% | -33.3% |
| Q2 2022 | $2,918,000 | -26.7% | 1,328,270 | +6.1% | 0.00% | 0.0% |
| Q1 2022 | $3,980,000 | -24.3% | 1,251,812 | -0.3% | 0.00% | -25.0% |
| Q4 2021 | $5,259,000 | -48.5% | 1,256,068 | -0.4% | 0.00% | -55.6% |
| Q3 2021 | $10,203,000 | +59.6% | 1,260,574 | +48.8% | 0.01% | +50.0% |
| Q2 2021 | $6,394,000 | -14.4% | 847,089 | -1.9% | 0.01% | -14.3% |
| Q1 2021 | $7,471,000 | +2.8% | 863,814 | -5.4% | 0.01% | -12.5% |
| Q4 2020 | $7,270,000 | +56.5% | 913,149 | +56.7% | 0.01% | +33.3% |
| Q3 2020 | $4,645,000 | – | 582,594 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |